title: Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
abstract: Abnormality of the B-cell receptor (BCR) signaling is correlated to origin of many B-cell malignancies. Bruton's tyrosine kinase (BTK), is described as a possible target in a many B-cell neoplasms. Ibrutinib is the most used inhibitor of BTK and has great tolerability and efficacy in chronic lymphocytic leukemia. This review summarizes results with ibrutinib in clinical trials and novel BTK inhibitors of interest.
authors.affiliation: Department of hematology, Azienda Ospedaliera Universitaria Senese, Policlinico S. Maria alle Scotte, viale Bracci 16, 53100 Siena, Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Gozzetti
authors.affiliation: Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, Italy.
authors.forename: Veronica
authors.initials: V
authors.lastname: Candi
authors.affiliation: Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, Italy.
authors.forename: Corrado Zuanelli
authors.initials: CZ
authors.lastname: Brambilla
authors.affiliation: Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, Italy.
authors.forename: Giulia
authors.initials: G
authors.lastname: Papini
authors.affiliation: Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, Italy.
authors.forename: Alberto
authors.initials: A
authors.lastname: Fabbri
authors.affiliation: Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, Italy.
authors.forename: Monica
authors.initials: M
authors.lastname: Bocchia
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000077329:Agammaglobulinaemia Tyrosine Kinase; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology*; D049109:Cell Proliferation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000378:metabolism; D015394:Molecular Structure; D010880:Piperidines; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011720:Pyrazoles / Q000737:chemistry / Q000494:pharmacology*; D011743:Pyrimidines / Q000737:chemistry / Q000494:pharmacology*; D013329:Structure-Activity Relationship
chemical_list: D000970:Antineoplastic Agents; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase; C000625949:BTK protein, human; D000225:Adenine
keywords: BCR; BTK; CLL; chemotherapy; kinase; tyrosine